Contemporary post-marketing adverse events and modes of failure related to VASCADE Vascular Closure System: The utility of the MAUDE database.
Citation: Catheterization & Cardiovascular Interventions. 99(3):822-826, 2022 02.PMID: 34480524Institution: MedStar Heart & Vascular Institute | MedStar Heart & Vascular Institute | MedStar Washington Hospital CenterDepartment: Advanced Cardiac Catheterization Research Fellowship | Interventional Cardiology FellowshipForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Femoral Artery | *Marketing | Databases, Factual | Femoral Artery/dg [Diagnostic Imaging] | Humans | Treatment Outcome | United States Food and Drug Administration | United States/ep [Epidemiology]Year: 2022ISSN:- 1522-1946
- Satler, Lowell F Waksman, Ron:
- https://orcid.org/0000-0001-6446-2683 https://orcid.org/0000-0002-4063-9226 https://orcid.org/0000-0001-6446-2683 https://orcid.org/0000-0002-4063-9226 Satler, Lowell F Waksman, Ron:
- https://orcid.org/0000-0001-6446-2683 https://orcid.org/0000-0002-4063-9226 https://orcid.org/0000-0001-6446-2683 https://orcid.org/0000-0002-4063-9226
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 34480524 | Available | 34480524 |
BACKGROUND: The VASCADE Vascular Closure System is a closure device for femoral arterial and venous access-site closure that was approved by the FDA in 2013. However, post-marketing data and experience on the most commonly reported complications and modes of failure associated with the VASCADE Vascular Closure System are limited.
CONCLUSIONS: Our analysis of the MAUDE database demonstrates that in contemporary post-marketing practice, physicians should be well-trained and educated to use the VASCADE closure device because improper utilization is a common cause of device failure, and complications with the VASCADE device can have profound clinical implications. Copyright (c) 2021 Wiley Periodicals LLC.
METHODS: Post-marketing surveillance data from the FDA MAUDE database from October 2013 through March 2020 were analyzed, yielding 201 reports.
OBJECTIVES: To analyze post-marketing surveillance data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database for the VASCADE Vascular Closure System (Cardiva Medical Inc., Santa Clara, CA).
RESULTS: Of the 201 reports of major complications involving VASCADE devices, 156 reports involved either injury (145) or death (11) related to the device. Of the 145 injury reports, bleeding was the most common adverse outcome described (85), followed by pseudoaneurysm (29) and pulselessness of an extremity (21). The device malfunction incidents (41 reports) were reported in three main categories, with deployment failure being the most commonly reported complication.
English